National Cancer Institute

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	N	NRG Oncology	Corpus Uteri	NCT05538897	NRG-GY028	Y	Bender	David	ET	19-Jul-2023		I/II	N	Tre	N	A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer		8	2	2		
INT	N	NRG Oncology	Corpus Uteri	NCT05112601	NRG-GY025	Y	Bender	David	ET	01-Sep-2022		II	N	Tre	N	A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma		5	1	3		
INT	N	NRG Oncology	Corpus Uteri	NCT05256225	NRG-GY026	Y	Bender	David	ET	10-Feb-2023		II/III	N	Tre	N	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma		5		1		
INT	N	NRG Oncology	Multiple	NCT05950464	NRG-GY031	Y	Bender	David	ET	04-Apr-2024		I	N	Tre	N	A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer		5	1	1		
INT	N	National Cancer Institute	Ovary	NCT04251052	NRG-CC008	Y	Bender	David	ET	24-Nov-2020		NA	N	Pre	N	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]		5	2	9		
INT	N	NRG Oncology	Ovary	NCT06169124	NRG-GY033	Y	Bender	David	ET	21-Mar-2024		II	N	Tre	N	A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor		3				
INT	N	NRG Oncology	Multiple	NCT04095364	NRG-GY019	Y	Bender	David	ET	18-Dec-2019		III	N	Tre	N	A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum		3	1	5		
INT	N	SWOG	Prostate	NCT03678025	S1802	Y	Caster	Joseph	ET	21-Aug-2020		III	N	Tre	N	Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer		7	1	6		
INT	N	NRG Oncology	Prostate	NCT04037254	NRG-GU007	Y	Caster	Joseph	ET	04-May-2020	01-Jul-2024	I/II	N	Tre	N	Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib with Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (with Initial Phase I)		10		1		
INT	N	SWOG	Multiple	NCT05564390	MYELOMATCH	Y	Dhakal	Prajwal	ET	24-Sep-2024		II	N	Scr	N	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials		25	3	3		
INT	N	Children's Oncology Group	Multiple	NCT03155620	APEC1621SC	Y	Dickens	David	CEPS	26-Apr-2018	23-Dec-2024	II	N	Scr	N	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol		16		3		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	N	Children's Oncology Group	Brain and Nervous System	NCT05382338	ACNS2031	Y	Dickens	David	CEPS	03-Mar-2023		III	N	Tre	N	A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features		1		1		
INT	N	Children's Oncology Group	Liver	NCT03533582	AHEP1531	Y	Dickens	David	CEPS	30-Aug-2018		III	N	Tre	N	Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)		7		3		
INT	N	Children's Oncology Group	Brain and Nervous System	NCT03126916	ANBL1531	Y	Dickens	David	CEPS	19-Oct-2018		III	N	Tre	N	A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)		7		6		
INT	N	Children's Oncology Group	Myeloid and Monocytic Leukemia	NCT04293562	AAML1831	Y	Dickens	David	CEPS	19-May-2021		III	N	Tre	N	A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations		4		7		
INT	N	Children's Oncology Group	Kidney	NCT04322318	AREN1921	Y	Dickens	David	CEPS	19-Feb-2021		II	N	Tre	N	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)		2				
INT	N	Children's Oncology Group	Bones and Joints	NCT05691478	AOST2032	Y	Dickens	David	CEPS	03-May-2023		II/III	N	Tre	N	A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma		2				
INT	N	National Cancer Institute	Multiple	NCT05602194	ACCL1931	Y	Dickens	David	CEPS	28-Nov-2023		III	N	Sup	N	A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy		10				
INT	N	Children's Oncology Group	Hodgkin Lymphoma	NCT05675410	AHOD2131	Y	Dickens	David	CEPS	19-Jul-2023		III	N	Tre	N	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma		2	1	3		
INT	N	Children's Oncology Group	Other Hematopoietic	NCT05828069	ANHL2121	Y	Dickens	David	CEPS	14-Jun-2023		II	N	Tre	N	Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis		1				
INT	N	Children's Oncology Group	Multiple	NCT03067181	AGCT1531	Y	Dickens	David	CEPS	30-Apr-2018		III	N	Tre	N	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors		5	1	8		
INT	N	Children's Oncology Group	Multiple	NCT02582697	AGCT1532	Y	Dickens	David	CEPS	19-Apr-2019		III	N	Tre	N	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors		7	1	2		
INT	N	Children's Oncology Group	Multiple	NCT03223753	ALTE1631	Y	Dickens	David	CEPS	04-Jun-2019	10-Jan-2025	III	N	Pre	N	A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Cancer		20		2		
INT	N	Children's Oncology Group	Multiple	NCT03213652	APEC1621F	Y	Dickens	David	CEPS	26-Apr-2018	30-Dec-2024	II	N	Tre	N	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations		2				

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	N	Children's Oncology Group	Soft Tissue	NCT05304585	ARST2032	Y	Dickens	David	CEPS	15-Nov-2022		III	N	Tre	N	A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma		6	2	3		
INT	N	Children's Oncology Group	Multiple	NCT05235165	AOST2031	Y	Dickens	David	CEPS	19-Oct-2022		III	N	Tre	N	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma		1				
INT	N	Children's Oncology Group	Brain and Nervous System	NCT05099003	ACNS1821	Y	Dickens	David	CEPS	28-Sep-2022		I/II	N	Tre	N	A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)		1	1	1		
INT	N	Children's Oncology Group	Brain and Nervous System	NCT03794349	ANBL1821	Y	Dickens	David	CEPS	31-Dec-2019	17-Oct-2024	II	N	Tre	N	A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma		5		1		
INT	N	Children's Oncology Group	Myeloid and Monocytic Leukemia	NCT03817398	AAML18P1	Y	Dickens	David	CEPS	03-Nov-2021	28-Jun-2024	II	Y	Tre	N	Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)		1				
INT	N	Children's Oncology Group	Lymphoid Leukemia	NCT03007147	AALL1631	Y	Dickens	David	CEPS	27-Jul-2018	01-Oct-2024	III	N	Tre	N	International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones		4		1		
INT	N	Children's Oncology Group	Brain and Nervous System	NCT03871257	ACNS1831	Y	Dickens	David	CEPS	27-Apr-2020		III	N	Tre	N	A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)		4	2	3		
INT	N	Children's Oncology Group	Multiple	NCT03914625	AALL1731	Y	Dickens	David	CEPS	16-Dec-2019	16-Aug-2024	III	N	Tre	N	A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)		8	5	22		
INT	N	Children's Oncology Group	Brain and Nervous System	NCT03919071	ACNS1723	Y	Dickens	David	CEPS	04-Feb-2020	10-Jan-2025	II	N	Tre	N	A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)		8		1		
INT	N	Children's Oncology Group	Soft Tissue	NCT04994132	ARST2031	Y	Dickens	David	CEPS	08-Nov-2021	13-Feb-2025	III	N	Tre	N	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)		2		1		
INT	N	Children's Oncology Group	Multiple	NCT03959085	AALL1732	Y	Dickens	David	CEPS	04-Feb-2020		III	N	Tre	N	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy		15	1	17		

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	N	Children's Oncology Group	Multiple	NCT05761171	AALL2121	Y	Dickens	David	CEPS	18-Mar-2024		II	N	Tre	N	A Phase 2 Study of Revumenib (SNDX-5613) in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia		2				
INT	N	Children's Oncology Group	Multiple	NCT06172296	ANBL2131	Y	Dickens	David	CEPS	14-Aug-2024		III	N	Tre	N	A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma		7				
INT	N	Children's Oncology Group	Multiple	NCT02981628	AALL1621	Y	Dickens	David	CEPS	13-Dec-2017		II	N	Tre	N	A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)		8				
INT	N	Children's Oncology Group	Non-Hodgkin Lymphoma	NCT04759586	ANHL1931	Y	Dickens	David	CEPS	03-Nov-2021		III	N	Tre	N	A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma		5	3	4		
INT	N	Children's Oncology Group	Multiple	NCT04726241	APAL2020SC	Y	Dickens	David	CEPS	15-Apr-2022		II	N	Scr	N	Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias		6	3	4		
INT	N	Children's Oncology Group	Brain and Nervous System	NCT04684368	ACNS2021	Y	Dickens	David	CEPS	01-Sep-2021		II	N	Tre	N	A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor		2				
INT	N	Children's Oncology Group	Brain and Nervous System	NCT04166409	ACNS1833	Y	Dickens	David	CEPS	22-Apr-2020		III	N	Tre	N	A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)		4		2		
INT	N	Children's Oncology Group	Brain and Nervous System	NCT04576117	ACNS1931	Y	Dickens	David	CEPS	28-Apr-2021		III	N	Tre	N	A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination with Vinblastine for Non-NF1, Non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations		6				
INT	N	National Cancer Institute	Brain and Nervous System	NCT04939597	ACCL2031	Y	Dickens	David	CEPS	10-Feb-2022		III	N	Sup	N	A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors		2				
INT	N	Children's Oncology Group	Lymphoid Leukemia	NCT04546399	AALL1821	Y	Dickens	David	CEPS	03-May-2021		II	N	Tre	N	A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse		4				
INT	N	Children's Oncology Group	Brain and Nervous System	NCT02724579	ACNS1422	Y	Dickens	David	CEPS	13-Dec-2017	13-Sep-2024	II	N	Tre	N	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients		6		1		
INT	N	ECOG-ACRIN Cancer Research Group	Multiple	NCT04628767	EA8192	Y	Farooq	Umar	ET	21-Feb-2022		II/III	N	Tre	N	A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy		8	1	3		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	N	Alliance for Clinical Trials in Oncology	Multiple	NCT03994796	A071701	Y	Farooq	Umar	ET	21-Apr-2020		II	N	Tre	N	Genomically-Guided Treatment Trial in Brain Metastases		5				
INT	N	Alliance for Clinical Trials in Oncology	Non-Hodgkin Lymphoma	NCT04803201	A051902	Y	Farooq	Umar	ET	01-Jun-2022		II	N	Tre	N	A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas		10				
INT	N	SWOG	Multiple Myeloma	NCT04071457	S1803	Y	Farooq	Umar	ET	14-Jul-2021	15-Jan-2025	III	N	Tre	N	Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)		20	2	9		
INT	N	ECOG-ACRIN Cancer Research Group	Lung	NCT02201992	E4512	Y	Furqan	Muhammad	ET	08-Feb-2016	10-May-2024	III	N	Tre	N	A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein		10		1		
INT	N	SWOG	Lung	NCT03851445	LUNGMAP	Y	Furqan	Muhammad	ET	15-May-2020		II/III	N	Oth	N	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)		40		20		
INT	N	Alliance for Clinical Trials in Oncology	Lung	NCT02194738	A151216	Y	Furqan	Muhammad	ET	08-Feb-2016	14-Mar-2025	NA	N	Scr	N	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)		50		21		
INT	N	ECOG-ACRIN Cancer Research Group	Lung	NCT03793179	EA5163	Y	Furqan	Muhammad	ET	19-May-2020	01-Mar-2024	III	N	Tre	N	EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis		10		3		
INT	N	National Cancer Institute	Multiple	NCT04939090	A222004	Y	Laux	Douglas	ET	06-Nov-2023	14-Mar-2025	III	N	Sup	N	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia		10				
INT	N	Alliance for Clinical Trials in Oncology	Multiple	NCT05432791	A092104	Y	Milhem	Mohammed	ET	01-Dec-2023	01-Oct-2024	II/III	N	Tre	N	A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy		8				
INT	N	Alliance for Clinical Trials in Oncology	Brain and Nervous System	NCT02523014	A071401	Y	Milhem	Mohammed	ET	27-Jan-2016		II	N	Tre	N	Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations		15		6		
INT	N	SWOG	Non-Hodgkin Lymphoma	NCT05633615	S2114	Y	Mou	Eric	ET	11-Aug-2024		II	N	Tre	N	A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma		8	2	2		
INT	N	Alliance for Clinical Trials in Oncology	Non-Hodgkin Lymphoma	NCT05976763	A052101	Y	Mou	Eric	ET	22-Mar-2024		III	N	Tre	N	A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)		6				
INT	N	SWOG	Non-Hodgkin Lymphoma	NCT03269669	S1608	Y	Mou	Eric	ET	18-Dec-2017	15-Jul-2024	II	N	Tre	N	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma		12		3		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	N	ECOG-ACRIN Cancer Research Group	Urinary Bladder	NCT05538663	EA8212	Y	O'Donnell	Michael	ET	28-Jul-2023		III	N	Tre	N	A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)		20	1	1		
INT	N	NRG Oncology	Lip, Oral Cavity and Pharynx	NCT04333537	NRG-HN006	Y	Pagedar	Nitin	CEPS	05-Jul-2022		II/III	N	Tre	N	Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer		30				
INT	N	Alliance for Clinical Trials in Oncology	Breast	NCT05812807	A012103	Y	Phadke	Sneha	CEPS	21-Feb-2024		III	N	Tre	N	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy		5	1	1		
INT	N	NRG Oncology	Breast	NCT05879926	NRG-BR009	Y	Phadke	Sneha	CEPS	12-Oct-2023		III	N	Tre	N	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)		15	1	2		
INT	N	National Cancer Institute	Breast	NCT05896189	NRG-CC011	Y	Phadke	Sneha	CEPS	23-Apr-2024		III	N	Pre	N	Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial		12	17	17		
INT	N	SWOG	Breast	NCT05929768	S2212	Y	Phadke	Sneha	CEPS	03-Oct-2024		III	N	Tre	N	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study		10	1	1		
INT	N	National Cancer Institute	Breast	NCT03233191	EA1151	Y	Policeni	Fabiana	FRMI	08-Oct-2020	20-Dec-2024	III	N	Scr	N	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)		200	26	109		
INT	N	ECOG-ACRIN Cancer Research Group	Prostate	NCT03697148	EA8171	Y	Rajput	Maheen	FRMI	07-Jun-2019	03-Mar-2025	II	N	Dia	N	Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer		25	11	76		
INT	N	ECOG-ACRIN Cancer Research Group	Soft Tissue	NCT06422806	EA7222	Y	Rieth	John	ET	04-Nov-2024		III	N	Tre	N	A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas		6				
INT	N	SWOG	Multiple Myeloma	NCT05561387	S2209	Y	Shaikh	Hira	ET	01-May-2024		III	N	Tre	N	A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance		6				
INT	N	NRG Oncology	Colon	NCT04068103	NRG-GI005	Y	Sharif	Saima	ET	01-Apr-2020	12-Feb-2024	II/III	N	Tre	N	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)		40				
INT	N	SWOG	Small Intestine	NCT04205968	S1922	Y	Sharif	Saima	ET	04-Aug-2020		II	N	Tre	N	Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma		6		1		
INT	N	NRG Oncology	Colon	NCT05174169	NRG-GI008	Y	Sharif	Saima	ET	03-Feb-2023		II/III	N	Tre	N	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)		6	4	4		

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	N	Alliance for Clinical Trials in Oncology	Multiple	NCT05677490	A022102	Y	Sharif	Saima	ET	06-Feb-2024		III	N	Tre	N	Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma		8				
INT	N	Children's Oncology Group	Multiple	NCT05457556	ASCT2031	Y	Sharma	Rajat	ET	23-Feb-2023		III	N	Tre	N	A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)		8				
INT	N	National Cancer Institute	Multiple	NCT05711667	ACCL1932	Y	Sharma	Rajat	ET	18-Sep-2024		III	N	Pre	N	Letermovir Prophylaxis for Cytomegalovirus in Pediatric Hematopoietic Cell Transplantation		15				
INT	N	ECOG-ACRIN Cancer Research Group	Multiple Myeloma	NCT03937635	EAA173	Y	Strouse	Christopher	CEPS	09-Mar-2023		III	N	Tre	N	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)		8	1	2		
INT	N	Alliance for Clinical Trials in Oncology	Myeloid and Monocytic Leukemia	NCT03701308	A041701	Y	Sutamtewagul	Grerk	ET	18-Oct-2019	16-Sep-2024	II/III	N	Tre	N	A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy		40		10		
INT	N	Alliance for Clinical Trials in Oncology	Lymphoid Leukemia	NCT03150693	A041501	Y	Sutamtewagul	Grerk	ET	02-Oct-2018		III	N	Tre	N	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL		12		1		
INT	N	Alliance for Clinical Trials in Oncology	Kidney	NCT04071223	A031801	Y	Zakharia	Yousef	ET	10-Jan-2023	04-Jun-2024	II	N	Tre	N	A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)		7				
INT	N	Alliance for Clinical Trials in Oncology	Multiple	NCT05092958	A032001	Y	Zakharia	Yousef	ET	07-Dec-2023	20-Mar-2024	III	N	Tre	N	MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer		12				
INT	N	Alliance for Clinical Trials in Oncology	Brain and Nervous System	NCT06325683	A072201	Y	Zeitler	William	ET	17-Dec-2024		II	N	Tre	N	Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma		10				
INT	E	National Cancer Institute	Lung	NCT02905591	201712770	N	Allen	Bryan	FRMI	18-Feb-2018		II	N	Tre	N	A Phase II Trial of Pharmacological Ascorbate with Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer	44	40	5	42		
INT	E	HHS, NIH, University of Iowa/Holden Comprehensive Cancer Center	Multiple		202012153	N	Ayyappan	Sabarish	ET	25-Mar-2021		NA	N	Bas	N	Evaluation of T Cell Activation and NK Cell Mediated Antibody Dependent Cellular Cytotoxicity of Cancer	10	10				
INT	E	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT06148636	202206110	N	Bushnell	David	FRMI	10-Nov-2023		I	N	Tre	N	A Phase 1, First-in-Human Clinical Trial of [212Pb] VMT-Alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine Tumors	24	6	4	7		
INT	E	LLS PedAL Initiative, LLC	Myeloid and Monocytic Leukemia	NCT05183035	ITCC-101/APAL2020D	Y	Dickens	David	CEPS	20-Apr-2023		III	N	Tre	N	A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML		1				

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	E	HHS, NIH	Multiple	NCT04533763	201911073	Y	Lutgendorf	Susan	CEPS	30-Sep-2020	19-Feb-2025	II	N	Sup	N	Living Well: A Web-Based Program to Improve Quality of Life in Rural and Urban Ovarian Cancer Survivors	256	350	18	164		
INT	E	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT05111509	202006288	N	Menda	Yusuf	FRMI	25-Oct-2022		Early Phase I	N	Dia	N	A Phase 0 First-In-Human Clinical Trial of [203Pb]VMT-a-NET SPECT/CT for Somatostatin Receptor Imaging of Neuroendocrine Tumors	20	9		10		
INT	E	University of Iowa/Holden Comprehensive Cancer Center	Other Endocrine System	NCT03335670	201708705	N	Menda	Yusuf	FRMI	03-Nov-2017		NA	Y	Dia	N	Biodistribution of Ga-68 Pentixafor in Patients with Neuroendocrine Tumors	30	30		5		
INT	E	SSM Health Saint Louis University Hospital	Bones and Joints	NCT03295981	28229	Y	Miller	Benjamin	CEPS	22-Apr-2019		III	N	Tre	N	Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: a Prospective Randomized Controlled Trial		20		11		
INT	E	Mayo Clinic in Rochester, National Cancer Institute	Multiple	NCT01787409	LS1293	Y	Mou	Eric	ET	06-Mar-2013		NA	N	Tre	N	Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients with Cancer		125	9	116		
INT	E	Fred Hutchinson Cancer Center	Multiple	NCT03779854	RG1003345	Y	Sharma	Rajat	ET	11-Feb-2020		II	N	Tre	N	Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults		20				
INT	I	JOINT LUNG CANCER TRIALISTS COALITION, UT Southwestern/Simmons Cancer Center-Dallas	Lung	NCT02468024	SCCC-02515; STU 022015-069	Y	Allen	Bryan	FRMI	05-Sep-2017		III	N	Tre	N	A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) - The STABLE-MATES Trial		15		3		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Brain and Nervous System	NCT04900792	202103125	N	Allen	Bryan	FRMI	31-Jan-2023		I	N	Tre	N	A First-in-Human Clinical Trial of Pharmacologic Ascorbate and Ferumoxytol Combined with Concomitant Temozolomide and External Beam Radiation Therapy for Newly Diagnosed Glioblastoma	16	6	10	17		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Lip, Oral Cavity and Pharynx	NCT04925700	202012278	N	Banas	Jeffrey	ET	13-Apr-2022	12-Mar-2024	NA	Y	Bas	N	The Oral Microbiome in Oral Squamous Cell Carcinoma	100	100		11		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple		201910759	N	Buatti	John	FRMI	24-Jan-2020		NA	Y	Dia	N	Unity MRI: Adoption of Additional Sequencing	500	500	7	29		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Rectum	NCT04926324	202103459	N	Caster	Joseph	ET	09-Jun-2022	21-Nov-2024	I/II	N	Tre	N	Phase 1b/2 Trial of Preoperative Niraparib, Dostarlimab, and Hypofractionated Radiotherapy for the Treatment of Locally-Advanced Rectal Cancers	41	41	1	3		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT05159050	202105008	N	Chan	Carlos	CGP	26-Apr-2022		I	N	Tre	N	Phase I Trial of Intraperitoneal Paclitaxel-Loaded Tumor Penetrating Microparticles (TPM) for Treatment of Peritoneal Carcinomatosis	30	10	1	4		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Kidney		202404637	N	Dalamaggas	Arianna	CEPS	02-Sep-2024		NA	Y	Dia	N	Assessing Sensitivity of Imaging Modalities in Detection of Metastatic Renal Cell Carcinoma to Bone	10	10				
INT	I	Giselle Sholler	Multiple	NCT04301843	BCC015	Y	Dickens	David	CEPS	22-Feb-2024		II	N	Tre	N	Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma		2	1	1		

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	I	Nationwide Children's Hospital	Brain and Nervous System	NCT02875314	NCH-15004	Y	Dickens	David	CEPS	11-Feb-2020	16-Jan-2025	IV	N	Tre	N	The "Head Start 4" Protocol Newly Diagnosed Children (Less than 10 Years Old) with Medulloblastoma and Other Central Nervous System Emrbyonal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to Either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue		5		1		
INT	I	Giselle Sholler	Multiple	NCT02679144	NMTRC014	Y	Dickens	David	CEPS	12-Apr-2024		II	N	Pre	N	NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)		3				
INT	I	Case Comprehensive Cancer Center	Non-Hodgkin Lymphoma	NCT05400109	CASE2422	Y	Farooq	Umar	ET	17-May-2023		I	N	Tre	N	A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas		5	1	3		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT03983668	201902747	N	Farooq	Umar	ET	31-Jan-2020	08-Nov-2024	I/II	N	Tre	N	Phase I/II Study of Pembrolizumab and In-Situ Injection of CMP-001 in Patients with Relapsed and Refractory Lymphomas	39	39	1	14		
INT	I	AstraZeneca Pharmaceuticals LP, University of Iowa/Holden Comprehensive Cancer Center	Lung	NCT06083454	202303162	N	Furqan	Muhammad	ET	23-Oct-2023		I	N	Tre	N	Assessing the Immunomodulatory Effects of Pharmacologic Ascorbate with Durvalumab (MEDI 4736) in Non-Small Cell Lung Cancer: A Window of Opportunity Trial	36	36				
INT	I	Genentech Inc., University of Kansas Cancer Center	Lung	NCT04467801	IIT-2019-IpatTax	Y	Furqan	Muhammad	ET	29-Aug-2023		II	N	Tre	N	A Multi-Center Phase II Study of Ipatasertib in Combination with Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)		10	1	2		
INT	I	Indiana University/Melvin and Bren Simon Cancer Center, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Lung	NCT04317534	CTO-BTCRC-LUN18-153	Y	Furqan	Muhammad	ET	11-Jan-2021		II	N	Tre	N	A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153		20	4	21		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Corpus Uteri	NCT06534008	202311588	N	Gorzelitz	Jessica	CEPS	17-Jul-2024		NA	Y	Sup	N	The Effect of Combined Aerobic and Muscle Strengthening Exercises on Structural and Functional Cardiovascular Adaptations in Endometrial Cancer Survivors	30	30	7	7		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple		202110112	N	Graham	Michael	FRMI	29-Dec-2022	16-Feb-2024	NA	N	Bas	N	Bioequivalence Study between DOTATOC and DOTATOC Cold Kit	20	10		7		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT06395402	202208502	N	Graves	Stephen	FRMI	25-Sep-2024		II	N	Tre	N	177LU-DOTATATE Modified Delivery Based on Individualized Dosimetry	105	105	2	2		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple		202403294	N	Groves	Andrew	ET	03-Sep-2024		NA	Y	Dia	N	Pharmacogenomic Testing in Children and Young Adults Receiving Care in the Pediatric Hematology/Oncology Clinic at the University of Iowa	100	20	1	1		

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	I	HHS, NIH	Multiple	NCT03382106	201706713	N	Hoffman	Eric	FRMI	19-Mar-2018		IV	N	Pre	N	Smoking Cessation and Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema	120	120	5	161		
INT	I	City of Hope Comprehensive Cancer Center	Thyroid	NCT05229341	21129	Y	Howe	James	CGP	22-Aug-2022		NA	N	Dia	N	Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules		750	104	255		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Soft Tissue	NCT03173976	201610743	N	Milhem	Mohammed	ET	18-Jul-2017	05-Jan-2024	I	N	Tre	N	Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial	15	15		17		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Kidney	NCT05363631	202104398	N	Milhem	Mohammed	ET	19-Sep-2022		I/II	N	Tre	N	Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination with Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)	48	48	1	10		
INT	I	McMaster Children's Hospital at Hamilton Health Sciences	Soft Tissue	NCT03944798	GHRT02	Y	Miller	Benjamin	CEPS	13-Aug-2020	04-Dec-2024	NA	N	Pre	N	Surveillance AFter Extremity Tumor surgerY (SAFETY) International Randomized Controlled Trial		50		7		
INT	I	Mayo Clinic in Rochester	Non-Hodgkin Lymphoma	NCT05507541	MC200802	Y	Mou	Eric	ET	21-Sep-2023		II	N	Tre	N	Phase 2 Study with Safety Run-in of PD-1 Inhibitor and IgG4 SIRPα-Fc Fusion Protein (TTI-622) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)		10	3	3		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple		202107332	N	Mozena	Emily	CEPS	11-Mar-2024		NA	N	Sup	N	Understanding Perspectives and Resilience of Adolescents with a Parent Diagnosed with Cancer	20	20	6	6		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple		202206354	N	Nakad	Lynn	CEPS	12-Jul-2023	26-Aug-2024	NA	N	Sup	N	The Effectiveness of a Virtual Reality Distraction Therapy for Breakthrough Cancer Pain in Patients with Cancer	25	25	3	15		
INT	I	Oana Danciu	Breast	NCT05467891	HCRN BRE20-468	Y	Phadke	Sneha	CEPS	22-Jun-2023		II	N	Tre	N	A Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer		8	2	3		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple		202405324	N	Powers	Jennifer	CEPS	10-Jun-2024		NA	N	Sup	N	Informed Patients, Improved Outcomes: Assessing the Impact of Supplemental Educational Videos in Mohs Micrographic Surgery	50	80	66	66		
INT	I	Medical College of Wisconsin	Multiple	NCT04040205	PRO34388	Y	Rieth	John	ET	15-Feb-2021		II	N	Tre	N	Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration		8	1	9		
INT	I	Exelixis Inc, University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT03957551	201904712	N	Rieth	John	ET	27-Aug-2019	03-Sep-2024	I/II	N	Tre	N	Cabozantinib and Pembrolizumab as a Front-Line Therapy for Advanced Metastatic Melanoma	62	39	1	28		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Soft Tissue	NCT04634227	201802800	N	Rieth	John	ET	11-Jul-2018	23-Jan-2025	II	Y	Tre	N	A Pilot Study of Gemcitabine plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults	20	29	1	29		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT06113809	202305133	N	Rieth	John	ET	01-Feb-2024		I	Y	Tre	N	Phase Ib Trial Evaluating the Combination of CDK4 Inhibitor with Immunotherapy in Patients with Undifferentiated Pleomorphic Sarcoma (UPS)	6	3	1	1		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Colon	NCT05239546	202105539	N	Sharif	Saima	ET	24-Mar-2023		II	N	Tre	N	Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers	25	10		2		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Breast	NCT06586047	202306462	N	Shariftabrizi	Ahmad	FRMI	09-Sep-2024		II	N	Dia	N	Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT	30	30	1	1		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple Myeloma		202206056	N	Shariftabrizi	Ahmad	FRMI	11-Mar-2024		NA	Y	Dia	N	Parametric PET for Multiple Myeloma	10	10	1	1		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple Myeloma	NCT03602235	201804754	N	Strouse	Christopher	CEPS	05-Mar-2019		I	N	Tre	N	High Dose Ascorbic Acid (HDAA) in Patients with Plasma Cell Disorders	18	9	2	6		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT05805436	202209015	N	Tracy	Chad	FRMI	11-May-2023		IV	N	Sup	N	The Use of Preoperative Osmotic Laxatives to Improve Recovery of Bowel Function after Robotic-Assisted Urologic Surgery	240	58	8	17		
INT	I	University of Iowa/Holden Comprehensive Cancer Center	Multiple	NCT05057676	202103542	N	Wahls	Terry	CEPS	30-Aug-2024		NA	Y	Sup	N	The Efficacy, Challenges, and Facilitators of Implementation of a Web-Based, Behavioral Lifestyle Intervention to Improve Cancer-Related Fatigue and Quality of Life among People with Cancer in Remission	100	400	7	7		
INT	D	RayzeBio, Inc.	Lung	NCT05595460	RYZ101-101	Y	Bender	David	ET	04-Apr-2024		I	N	Tre	N	Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)		5	1	1		
INT	D	Nykode Therapeutics ASA	Cervix	NCT06099418	VB-C-04	Y	Bender	David	ET	19-Jun-2024	13-Dec-2024	II	N	Tre	N	A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab.		6				
INT	D	Nuvectis Pharma, Inc.	Multiple	NCT05226507	NXP800-101	Y	Bender	David	ET	01-Jul-2024		I	N	Tre	N	A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer		5				
INT	D	Abbvie	Ovary	NCT05445778	IMGN853-0421	Y	Bender	David	ET	05-Oct-2023		III	N	Tre	N	Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)		12	2	2		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Sutro Biopharma	Multiple	NCT05870748	STRO-002-GM 3	Y	Bender	David	ET	13-Aug-2024		II/III	N	Tre	N	REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)		5				
INT	D	RayzeBio, Inc.	Multiple	NCT05477576	RYZ101-301	Y	Bushnell	David	FRMI	03-Oct-2023		III	N	Tre	N	Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment with RYZ101 to Standard of Care Therapy in Subjects with Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy		7	4	7		
INT	D	Merck Sharp & Dohme LLC	Lung	NCT06077760	V940-002	Y	Byrne	Margaret	ET	22-Aug-2024		III	N	Tre	N	A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)		8				
INT	D	Nucana PLC	Multiple	NCT05678257	NuTide:323	Y	Chandrasek haran	Chandrikha	ET	21-Sep-2023	08-Mar-2024	II	N	Tre	N	A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer		8				
INT	D	Astellas Pharma Global Development, Inc.	Multiple	NCT05646797	2074-CL-0101	Y	Chandrasek haran	Chandrikha	ET	09-Aug-2023	04-Apr-2024	I	N	Tre	N	A Phase 1/1b Study of ASP2074 in Participants With Metastatic or Locally Advanced Solid Tumors		10				
INT	D	Nerviano Medical Sciences	Myeloid and Monocytic Leukemia	NCT03922100	MKIA-088-001	Y	Dhakal	Prajwal	ET	14-Mar-2024	02-Jan-2025	I/II	N	Tre	N	A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMML		8				
INT	D	Chimerix	Brain and Nervous System	NCT04617002	ONC028	Y	Dickens	David	CEPS	30-Apr-2021		NA	N	Oth	N	Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas		15	3	10		
INT	D	Chimerix	Brain and Nervous System	NCT05580562	ONC201-108	Y	Dickens	David	CEPS	24-Aug-2023		III	N	Tre	N	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study		1	1	1		
INT	D	Syndax Pharmaceuticals	Multiple	NCT05918913	SNDX-5613-0707	Y	Dickens	David	CEPS	19-Jan-2024		NA	N	Oth	N	Expanded Access Program for SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemias With Genetic Alterations Associated With HOXA Overexpression		5	4	4		
INT	D	Merck Sharp & Dohme LLC	Multiple	NCT06395103	9999-01A	Y	Dickens	David	CEPS	29-Aug-2024		I/II	N	Tre	N	LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors		3				

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Syndax Pharmaceuticals	Multiple	NCT04065399	SNDX-5613-0700	Y	Dickens	David	CEPS	11-Jun-2021		I/II	N	Tre	N	A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation		12		5		
INT	D	Fate Therapeutics	Multiple	NCT04629729	FT819-101	Y	Farooq	Umar	ET	25-Apr-2022	11-Mar-2024	I	N	Tre	N	A Phase I Study of FT819 in Subjects With B-cell Malignancies		10		8		
INT	D	Kite, A Gilead Company	Non-Hodgkin Lymphoma	NCT05605899	KT-US-484-0136	Y	Farooq	Umar	ET	25-Nov-2024		III	N	Tre	N	An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)		5				
INT	D	Janssen Research & Development, LLC	Non-Hodgkin Lymphoma	NCT05421663	90014496LYM1001	Y	Farooq	Umar	ET	07-Oct-2024		I	N	Tre	N	A Phase 1b Multicenter, Open-Label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-Cell Non-Hodgkin Lymphoma		8				
INT	D	Kite, A Gilead Company	Multiple	NCT05537766	KT-US-568-0138	Y	Farooq	Umar	ET	19-Jun-2023	10-May-2024	II	N	Tre	N	A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)		6				
INT	D	Janssen Research & Development, LLC	Multiple Myeloma	NCT04923893	CR109015	Y	Farooq	Umar	ET	08-Jul-2022	01-Jul-2024	III	N	Tre	N	A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy		20	1	10		
INT	D	Janssen Research & Development, LLC	Non-Hodgkin Lymphoma	NCT05784441	90009530LYM1001	Y	Farooq	Umar	ET	14-Dec-2023		I	N	Tre	N	A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma		10	5	5		
INT	D	Genmab	Non-Hodgkin Lymphoma	NCT03625037	GCT3013-01	Y	Farooq	Umar	ET	26-Mar-2021	19-Mar-2024	I/II	N	Tre	N	A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma		10		13		
INT	D	Caribou Biosciences, Inc.	Non-Hodgkin Lymphoma	NCT04637763	CB10A	Y	Farooq	Umar	ET	20-Jan-2023		I	N	Tre	N	A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)		5	2	3		
INT	D	CARGO Therapeutics	Non-Hodgkin Lymphoma	NCT05972720	CRG-022-101	Y	Farooq	Umar	ET	31-Jan-2024	30-Jan-2025	II	N	Tre	N	An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy		10				

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Juno Therapeutics, a Subsidiary of Celgene	Multiple	NCT04400591	JCAR017-EAP-001	Y	Farooq	Umar	ET	19-Feb-2021		NA	N	Oth	N	Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release		3	2	4		
INT	D	Artiva Biotherapeutics, Inc.	Non-Hodgkin Lymphoma	NCT04673617	AB-101-01	Y	Farooq	Umar	ET	11-Jan-2022	18-Apr-2024	I/II	N	Tre	N	A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.		6		7		
INT	D	Adicet Therapeutics	Non-Hodgkin Lymphoma	NCT04735471	ADI-20200101	Y	Farooq	Umar	ET	29-Aug-2022	26-Sep-2024	I	N	Tre	N	A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies		5	1	7		
INT	D	Lyell Immunopharma, Inc.	Non-Hodgkin Lymphoma	NCT05826535	MPCT-012L	Y	Farooq	Umar	ET	21-Sep-2023		I/II	N	Tre	N	A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma		8	5	7		
INT	D	Arsenal Biosciences, Inc.	Kidney	NCT06245915	AB-2100-201	Y	Farooq	Umar	ET	29-Mar-2024		I/II	N	Tre	N	An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-2100 in Patients with Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (ccRCC)		10	4	4		
INT	D	Regeneron Pharmaceuticals, Inc.	Non-Hodgkin Lymphoma	NCT03888105	R1979-ONC-1625	Y	Farooq	Umar	ET	11-Aug-2021		II	N	Tre	N	An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma		8	1	5		
INT	D	Arsenal Biosciences, Inc.	Multiple	NCT05617755	AB-1015-101	Y	Farooq	Umar	ET	22-Nov-2022	04-Sep-2024	I	N	Tre	N	An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients with Resistant/Refractory Epithelial Ovarian Cancer		8		6		
INT	D	Elicio Therapeutics	Multiple	NCT05726864	ELI-002-201	Y	Fei	Naomi	ET	28-Feb-2024	07-Jan-2025	I/II	N	Tre	N	First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors		8	3	3		
INT	D	Astellas Pharma Global Development, Inc.	Pancreas	NCT03816163	8951-CL-5201	Y	Fei	Naomi	ET	08-Jun-2023	22-Feb-2024	II	N	Tre	N	A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma		6				
INT	D	RenovoRx	Pancreas	NCT03257033	RR3 [CP-03-001]	Y	Fei	Naomi	ET	14-Oct-2019		III	N	Tre	N	Targeted Intra-arterial Gemcitabine Vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer		24	1	14		
INT	D	Astellas Pharma Global Development, Inc.	Multiple	NCT05719558	1002-CL-0101	Y	Furqan	Muhammad	ET	24-Aug-2023		I	N	Tre	N	A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors		15	2	4		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	AstraZeneca Pharmaceuticals LP	Lung	NCT03833154	D9103C00001	Y	Furqan	Muhammad	ET	30-Jun-2020		III	N	Tre	N	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients with Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation		15		2		
INT	D	Amgen, Inc.	Multiple	NCT04185883	20190135	Y	Furqan	Muhammad	ET	01-Apr-2021	18-Dec-2024	I	N	Tre	N	A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)		12		13		
INT	D	Immunocore Limited	Multiple	NCT04262466	IMC-F106C-101	Y	Furqan	Muhammad	ET	02-May-2023		I/II	N	Tre	N	Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers		10	1	2		
INT	D	Genmab	Multiple	NCT03917381	GCT1046-01	Y	Furqan	Muhammad	ET	20-Oct-2020	15-Jan-2024	I/II	N	Tre	N	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors		15		11		
INT	D	Inhibrx Biosciences, Inc	Multiple	NCT04198766	Ph 1 Ph 2 INBRX-106	Y	Furqan	Muhammad	ET	17-Jun-2021		I/II	N	Tre	N	An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors		15	10	34		
INT	D	Muhammad Furqan	Lung	NCT04699838	BTCRC-LUN18-363	Y	Furqan	Muhammad	ET	30-Apr-2021	21-Feb-2024	II	N	Tre	N	A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363		10		13		
INT	D	AstraZeneca Pharmaceuticals LP	Urinary Bladder	NCT04960709	D910PC00001	Y	Furqan	Muhammad	ET	23-Jan-2024	31-Dec-2024	III	N	Tre	N	A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)		10	3	3		
INT	D	NiKang Therapeutics Inc	Kidney	NCT05119335	NKT2152-101	Y	Furqan	Muhammad	ET	29-Sep-2022		I/II	N	Tre	N	Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma		12	2	5		
INT	D	Poseida Therapeutics, Inc.	Multiple	NCT05239143	P-MUC1C-ALLO1-001	Y	Furqan	Muhammad	ET	29-Nov-2023	25-Feb-2025	I	N	Tre	N	A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects with Advanced or Metastatic Solid Tumors		10	2	3		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Dwight Owen	Lung	NCT04919382	BTCRC LUN20-462	Y	Furqan	Muhammad	ET	03-Mar-2023		II	N	Tre	N	A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer		8	4	10		
INT	D	AstraZeneca Pharmaceuticals LP	Lung	NCT05687266	D926NC00001	Y	Furqan	Muhammad	ET	29-Aug-2023	29-Aug-2024	III	N	Tre	N	A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)		12	6	6		
INT	D	Amgen, Inc.	Lung	NCT05740566	20210004	Y	Furqan	Muhammad	ET	23-Feb-2024	06-May-2024	III	N	Tre	N	A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy		10				
INT	D	Abbvie	Multiple	NCT05599984	M23-385	Y	Furqan	Muhammad	ET	07-Nov-2023		I	N	Tre	N	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors		14	16	16		
INT	D	Hirva Mamdani	Lung	NCT05903092	HCRN LUN21-530	Y	Furqan	Muhammad	ET	10-Apr-2024		II	N	Tre	N	A Phase II Trial of MOnaliZumab in Combination with DurvAlumab (MEDI4736) Plus Platinum-based ChemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)		7	6	6		
INT	D	BeiGene	Multiple	NCT05935098	BGB-A317-A3055-101	Y	Furqan	Muhammad	ET	08-Dec-2023		I	N	Tre	N	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors		20	6	6		
INT	D	Seagen, a wholly owned subsidiary of Pfizer	Multiple	NCT05983133	SGNEGFRd2-001	Y	Furqan	Muhammad	ET	11-Mar-2024		I	N	Tre	N	A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors		15	4	4		
INT	D	CellSight Technologies, Inc.	Lung	NCT06084806	CST-FARAG-IO-UIOW-201-TRT	N	Furqan	Muhammad	ET	03-Nov-2023		II	N	Dia	N	Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients		10	3	3		
INT	D	SystImmune Inc.	Lung	NCT05983432	BL-B01D1-LUNG-101	Y	Furqan	Muhammad	ET	26-Sep-2024		I	N	Tre	N	A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors		6	4	4		
INT	D	CellSight Technologies, Inc.	Lung	NCT06107374	CST-FARAG-IO-UIOW-201	N	Furqan	Muhammad	ET	21-Sep-2023		II	N	Dia	N	Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy		20				
INT	D	Day One Biopharmaceuticals, Inc.	Brain and Nervous System	NCT05760586	DAY101-EAP	Y	Groves	Andrew	ET	25-May-2023	23-Jul-2024	NA	N	Oth	N	Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Relapsed or Refractory Low-Grade Glioma		5				

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Acrivon Therapeutics	Multiple	NCT05548296	ACR-368-201 (GOG 3082)	Y	Hill	Emily	CEPS	02-Feb-2024		I/II	N	Tre	N	A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status		15				
INT	D	MeiraGTx LLC	Multiple	NCT05926765	MGT-AQP1-201	Y	Hoffman	Henry	FRMI	03-Nov-2023		II	N	Tre	N	A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia		20	3	3		
INT	D	IDEAYA Biosciences	Eye and Orbit	NCT05987332	IDE196-002	Y	Javed	Asad	ET	02-Feb-2024		II/III	N	Tre	N	IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator's Choice of Treatment As First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)		10	4	4		
INT	D	Merck Sharp & Dohme LLC	Multiple	NCT03486873	3475-587	Y	Javed	Asad	ET	29-Jan-2019		III	N	Tre	N	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab		1		1		
INT	D	Replimune Inc.	Eye and Orbit	NCT06581406	RP2-202	Y	Javed	Asad	ET	19-Nov-2024		II/III	N	Tre	N	A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma		10				
INT	D	Lyell Immuno pharma, Inc.	Multiple	NCT05573035	LYL845-101	Y	Javed	Asad	ET	28-Dec-2023	29-Oct-2024	I	N	Tre	N	A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies		10				
INT	D	Merck Sharp & Dohme LLC	Other Skin	NCT06295809	V940-007	Y	Laux	Douglas	ET	09-Oct-2024	19-Dec-2024	II/III	N	Tre	N	A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007).		30				
INT	D	Ascendis Pharma A/S	Multiple	NCT05980598	ASND0038	Y	Laux	Douglas	ET	19-Nov-2024	22-Nov-2024	II	N	Tre	N	BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma		10				
INT	D	Astellas Pharma Global Development, Inc.	Multiple	NCT06171178	1012-CL-0101	Y	Laux	Douglas	ET	22-Apr-2024		I	N	Tre	N	A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants With Locally Advanced or Metastatic Solid Tumors		15	5	5		
INT	D	Ascendis Pharma Oncology Division A/S	Multiple	NCT04799054	TCTLR-101	Y	Laux	Douglas	ET	21-Feb-2022		I/II	N	Tre	N	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies		10	7	12		

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	NYP/Weill Cornell Medical Center	Multiple	NCT05583708	22-10025228	N	Laux	Douglas	ET	22-Mar-2024		II	N	Tre	N	A Single Arm Study With Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Immunotherapy for Patients With Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)		8				
INT	D	Seagen Inc.	Multiple	NCT04609566	SGN35-033	Y	Laux	Douglas	ET	30-Sep-2021	06-May-2024	II	N	Tre	N	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies		10	1	7		
INT	D	BicycleTx Limited	Multiple	NCT05163041	BT7480-100	Y	Laux	Douglas	ET	05-Jul-2022		I/II	N	Tre	N	Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies		15		2		
INT	D	Seagen Inc.	Multiple	NCT05208762	SGNPDL1V-001	Y	Laux	Douglas	ET	05-Jan-2024		I	N	Tre	N	A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors		10	3	3		
INT	D	Merck Sharp and Dohme LLC	Other Skin	NCT03833167	3475-630	Y	Laux	Douglas	ET	11-May-2020	29-Mar-2024	III	N	Tre	N	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)		30		2		
INT	D	Merck Sharp & Dohme LLC	Prostate	NCT06136624	5684-003	Y	Laux	Douglas	ET	15-Oct-2024		III	N	Tre	N	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)		7				
INT	D	Regeneron Pharmaceuticals, Inc.	Multiple	NCT04626635	R7075-ONC-2009	Y	Laux	Douglas	ET	25-Jul-2024		I/II	N	Tre	N	A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors		16	4	4		
INT	D	GlaxoSmithKline	Multiple	NCT06062420	219885	Y	Laux	Douglas	ET	24-Jun-2024		II	N	Tre	N	A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck		10				
INT	D	Hookipa Biotech GmbH	Multiple	NCT04180215	H-200-001	Y	Laux	Douglas	ET	01-Jul-2022	25-Oct-2024	I/II	N	Tre	N	A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers		8	3	6		
INT	D	Merck Sharp & Dohme LLC	Multiple	NCT04924075	6482-015	Y	Laux	Douglas	ET	27-Apr-2022		II	N	Tre	N	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations		8		3		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Kura Oncology, Inc.	Multiple	NCT06026410	KO-2806-001	Y	Laux	Douglas	ET	11-Sep-2024		I	N	Tre	N	Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors		10	1	1		
INT	D	Bristol-Myers Squibb	Multiple	NCT04895709	CA052-002	Y	Laux	Douglas	ET	25-Apr-2024		I/II	N	Tre	N	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors		12	1	1		
INT	D	Incyte Biosciences International Sàrl	Multiple	NCT05287113	INCAGN 2385-203	Y	Laux	Douglas	ET	21-Jul-2023	24-Apr-2024	II	N	Tre	N	A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck		14				
INT	D	GlaxoSmithKline	Multiple	NCT06256588	221530	Y	Laux	Douglas	ET	09-Oct-2024		III	N	Tre	N	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma		30				
INT	D	Exelixis Inc	Multiple	NCT06082167	XL092-305; KEYNOTE-G06	Y	Laux	Douglas	ET	20-Nov-2024		II/III	N	Tre	N	A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma		8				
INT	D	Regeneron Pharmaceuticals, Inc.	Multiple	NCT04916002	CMP-001-009	Y	Laux	Douglas	ET	12-Feb-2024	18-Jul-2024	II	N	Tre	N	A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer		10				
INT	D	Oxford BioTherapeutics Ltd	Multiple	NCT04064359	OBT076-001	Y	Laux	Douglas	ET	04-Oct-2022		I	N	Tre	N	A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors		10	2	4		
INT	D	Protagonist Therapeutics, Inc.	Multiple	NCT05210790	PTG-300-11	Y	Lentz	Steven	CGP	20-Jan-2023	20-Mar-2024	III	N	Tre	N	A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera		5				
INT	D	Novartis Pharmaceuticals Corporation	Multiple	NCT04939610	CO-2286-114	Y	Menda	Yusuf	FRMI	20-Jul-2022		I/II	N	Tre	N	LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor		4	10	18		
INT	D	Perspective Therapeutics	Melanoma, Skin	NCT05655312	VMT01-T101	Y	Menda	Yusuf	FRMI	30-Nov-2023		I/II	N	Tre	N	A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Escalation and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma		10	3	3		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Fusion Pharmaceuticals Inc.	Prostate	NCT06402331	FPI-2265-202	Y	Menda	Yusuf	FRMI	08-Nov-2024		II/III	N	Tre	N	A Phase 2/3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC), Previously Treated With 177Lu-PSMA Radioligand Therapy (RLT)		60	2	2		
INT	D	Inhibrx Biosciences, Inc	Bones and Joints	NCT04950075	Ph2 INBRX-109 SA CS	Y	Milhem	Mohammed	ET	21-Nov-2023		II	N	Tre	N	A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma		5		2		
INT	D	Merck Sharp and Dohme LLC	Melanoma, Skin	NCT05665595	7684A-010	Y	Milhem	Mohammed	ET	09-Nov-2023	06-Nov-2024	III	N	Tre	N	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)		15	2	4		
INT	D	Xilio Development, Inc.	Multiple	NCT05052268	XTX202-01/02-001	Y	Milhem	Mohammed	ET	13-Dec-2022	24-May-2024	I/II	N	Tre	N	A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors		12		15		
INT	D	Replimune Inc.	Multiple	NCT03767348	RPL-001-16	Y	Milhem	Mohammed	ET	08-Oct-2019	28-Mar-2024	II	N	Tre	N	An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors		30	4	51		
INT	D	Merck Sharp and Dohme LLC	Melanoma, Skin	NCT05933577	V940-001	Y	Milhem	Mohammed	ET	21-Feb-2024		III	N	Tre	N	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)		10	4	4		
INT	D	Genentech Inc.	Melanoma, Skin	NCT04835805	GO42273	Y	Milhem	Mohammed	ET	18-Nov-2021	04-Mar-2024	I	N	Tre	N	A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy		15		1		
INT	D	Philogen SPA	Melanoma, Skin	NCT03567889	PH-L19IL2TNF-01/18	Y	Milhem	Mohammed	ET	16-Feb-2023	06-Nov-2024	III	N	Tre	N	An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients		10		2		
INT	D	TopAlliance Biosciences	Multiple	NCT04137900	TAB004-01	Y	Milhem	Mohammed	ET	28-Oct-2021	27-Feb-2024	I	N	Tre	N	A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma		15		23		
INT	D	Replimune Inc.	Melanoma, Skin	NCT06264180	RP1-104	Y	Milhem	Mohammed	ET	31-Jul-2024		III	N	Tre	N	Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment		10				

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Merck Sharp & Dohme LLC	Urinary Bladder	NCT06305767	V940-005	Y	Milhem	Mohammed	ET	15-Oct-2024		I/II	N	Tre	N	A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)		15				
INT	D	Seagen, a wholly owned subsidiary of Pfizer	Multiple	NCT05571839	SGNBB228-001	Y	Milhem	Mohammed	ET	22-Feb-2024	09-Jul-2024	I	N	Tre	N	A Phase 1 Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors		10				
INT	D	Hoffmann-La Roche	Non-Hodgkin Lymphoma	NCT06047080	GO44145	Y	Mou	Eric	ET	16-May-2024		III	N	Tre	N	A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma		2	1	1		
INT	D	Hoffmann-La Roche	Non-Hodgkin Lymphoma	NCT04980222	GO43075	Y	Mou	Eric	ET	09-Aug-2022		II	N	Tre	N	A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma		20		9		
INT	D	BeiGene	Lymphoid Leukemia	NCT06073821	BGB-11417-301	Y	Mou	Eric	ET	29-Jul-2024	03-Mar-2025	III	N	Tre	N	A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia		3	1	1		
INT	D	BeiGene Company Limited	Multiple	NCT05006716	BGB-16673-101	Y	Mou	Eric	ET	12-Nov-2023		I/II	N	Tre	N	A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies		20	3	4		
INT	D	Seagen, a wholly owned subsidiary of Pfizer	Multiple	NCT06120504	SGN35T-001	Y	Mou	Eric	ET	27-Jun-2024		I	N	Tre	N	An Open-label Phase 1 Study to Evaluate the Safety of SGN-35T in Adults With Advanced Malignancies		12				
INT	D	Noah Hahn, M.D.	Urinary Bladder	NCT03317158	HCRN GU16-243	Y	O'Donnell	Michael	ET	14-Jan-2019		I/II	N	Tre	N	PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER		20	1	1		
INT	D	Olema Pharmaceuticals, Inc.	Breast	NCT05508906	OP-1250-003	Y	Phadke	Sneha	CEPS	05-Sep-2023		I	N	Tre	N	A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, or With the mTOR Inhibitor Everolimus in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer		6				

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Boehringer Ingelheim Pharmaceuticals Inc	Multiple	NCT06324357	1479-0012	Y	Phadke	Sneha	CEPS	03-Dec-2024		I/II	N	Tre	N	Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)		6				
INT	D	AstraZeneca Pharmaceuticals LP	Breast	NCT05774951	D8531C00002	Y	Phadke	Sneha	CEPS	02-Jan-2024		III	N	Tre	N	CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence		10	3	3		
INT	D	AstraZeneca Pharmaceuticals LP	Breast	NCT05629585	D926XC00001	Y	Phadke	Sneha	CEPS	13-Dec-2023		III	N	Tre	N	A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)		8				
INT	D	Arvinas Inc.	Breast	NCT05549505	ARV-471-BC-201	Y	Phadke	Sneha	CEPS	04-Oct-2023	15-Mar-2024	II	N	Tre	N	An Open-label, Randomized, Non-comparative Phase 2 Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting		6				
INT	D	Stemline Therapeutics Inc	Breast	NCT05386108	ELA-0121	Y	Phadke	Sneha	CEPS	20-Jul-2023	19-Jan-2024	I/II	N	Tre	N	An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer		5				
INT	D	Hoffmann-La Roche	Breast	NCT04873362	WO42633	Y	Phadke	Sneha	CEPS	12-Dec-2021	24-May-2024	III	N	Tre	N	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy		15		1		
INT	D	Lantheus Medical Imaging	Prostate	NCT06074510	PYL4301	Y	Pollard	Janet	FRMI	24-Sep-2024		IV	N	Dia	N	A Phase 4 Open-Label Multicenter Study of PYLARIFY® PET/CT or PET/MRI in Men with Newly Diagnosed Favorable Intermediate Risk (FIR) Prostate Cancer		10	1	1		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Novartis Pharmaceuticals Corporation	Prostate	NCT04720157	CAAA617C12301	Y	Pollard	Janet	FRMI	04-Apr-2023		III	N	Tre	N	An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)		15				
INT	D	Curium US LLC	Prostate	NCT06235099	CURCu64PSM0002	Y	Pollard	Janet	FRMI	24-Sep-2024		III	N	Dia	N	A Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men With Biochemical Recurrence of Prostate Cancer		20				
INT	D	Curium US LLC	Prostate	NCT06235151	CURCu64PSM0003	Y	Pollard	Janet	FRMI	24-Sep-2024		III	N	Dia	N	Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging Men With Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy With Pelvic Lymph Node Dissection		10				
INT	D	Incyte Corporation	Other Hematopoietic	NCT04279847	INCB 57643-103	Y	Poonsombudlert	Kittika	ET	23-Oct-2024		I	N	Tre	N	A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms		5				
INT	D	Xencor, Inc.	Prostate	NCT05005728	XmAb20717-04	Y	Rahim	Bilal	ET	06-Jul-2023	13-Nov-2024	II	N	Tre	N	Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer		9		3		
INT	D	Polaris Group	Soft Tissue	NCT05712694	POLARIS2022-001	Y	Rieth	John	ET	22-May-2024		III	N	Tre	N	ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): a Randomized, Double Blind, Multi-Center Phase 3 Trial		6				
INT	D	Cogent Biosciences Inc	Multiple	NCT05208047	CGT9486-21-301	Y	Rieth	John	ET	06-Jan-2023	11-Sep-2024	III	N	Tre	N	A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors		3	1	3		
INT	D	Ascentage Pharma Group Inc.	Multiple	NCT03611868	APG-115-US-002	Y	Rieth	John	ET	07-Oct-2024		I/II	N	Tre	N	A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors		10				
INT	D	Pfizer Inc	Multiple Myeloma	NCT05675449	C1071020	Y	Shaikh	Hira	ET	19-Jun-2023		I	N	Tre	N	A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA		10	1	6		
INT	D	Bexion Pharmaceuticals, Inc.	Multiple	NCT05322590	BXQ-350.AG	Y	Sharif	Saima	ET	20-Oct-2023		I/II	N	Tre	N	A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma		12		1		

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	CG Pharmaceuticals, Inc	Pancreas	NCT05249101	CG-745-2-08	Y	Sharif	Saima	ET	08-Sep-2023		I/II	N	Tre	N	A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat Plus Capecitabine or Capecitabine in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on FOLFIRINOX		6	1	1		
INT	D	Equillium	Multiple	NCT05263999	EQ-100-02	Y	Silverman	Margarida	ET	06-Apr-2023	30-Jan-2024	III	N	Tre	N	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease		5				
INT	D	Allovir	Lung	NCT04933968	P-106-001	Y	Silverman	Margarida	ET	16-Dec-2021		I/II	N	Tre	N	Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant		3				
INT	D	Marker Therapeutics, Inc.	Myeloid and Monocytic Leukemia	NCT04511130	MRKR-19-401	Y	Silverman	Margarida	ET	27-Jan-2021	16-Jan-2024	II	N	Tre	N	A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation		15		11		
INT	D	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Multiple Myeloma	NCT06297226	CA088-1000	Y	Strouse	Christopher	CEPS	25-Apr-2024		II	N	Tre	N	A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)		5	3	3		
INT	D	Stichting European Myeloma Network	Multiple Myeloma	NCT05257083	EMN28/68284528MMY3005	Y	Strouse	Christopher	CEPS	28-Oct-2024		III	N	Tre	N	A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible		5	4	4		
INT	D	Janssen Research & Development, LLC	Multiple Myeloma	NCT04133636	CR108581	Y	Strouse	Christopher	CEPS	09-May-2024	11-Feb-2025	II	N	Tre	N	A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma		9	2	2		
INT	D	Poseida Therapeutics, Inc.	Multiple Myeloma	NCT04960579	P-BCMA-ALLO1-001	Y	Strouse	Christopher	CEPS	02-Nov-2023		I	N	Tre	N	Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)		8	3	5		
INT	D	Celgene	Multiple Myeloma	NCT04771078	BB2121-EAP-001	Y	Strouse	Christopher	CEPS	28-May-2021		NA	N	Oth	N	Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release		3		2		
INT	D	Janssen Scientific Affairs, LLC	Multiple Myeloma	NCT05346835	CR108968	Y	Strouse	Christopher	CEPS	27-Jul-2023		NA	N	Oth	N	Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma		10	4	4		

CTRP Data Table 4 Report (Interventional) **Cancer Center: Holden Comprehensive Cancer Center** **Date Range: 01-Jan-2024 to 31-Dec-2024** **Date Printed: 23-Mar-2025**

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Janssen Research & Development, LLC	Multiple Myeloma	NCT06577025	54767414MMY2093	Y	Strouse	Christopher	CEPS	20-Aug-2024		II	N	Tre	N	A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma		2	2	2		
INT	D	Kura Oncology Inc	Myeloid and Monocytic Leukemia	NCT05735184	KO-MEN-007	Y	Sutamtewagul	Grerk	ET	13-Sep-2024		I	N	Tre	N	Phase 1 Study of Venetoclax/azacitidine or Venetoclax in Combination with Ziftomenib or Standard Induction Cytarabine/daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia		15	1	1		
INT	D	Merck Sharp & Dohme LLC	Multiple	NCT06136559	1026-011	Y	Sutamtewagul	Grerk	ET	25-Apr-2024		III	N	Tre	N	A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)		10	2	2		
INT	D	Arog Pharmaceuticals, Inc.	Myeloid and Monocytic Leukemia	NCT03258931	ARO-021	Y	Sutamtewagul	Grerk	ET	13-Nov-2019	29-Jul-2024	III	N	Tre	N	Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia		10		4		
INT	D	Syros Pharmaceuticals	Other Hematopoietic	NCT04797780	SY-1425-301	Y	Sutamtewagul	Grerk	ET	19-Aug-2021	13-Nov-2024	III	N	Tre	N	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)		10	2	3		
INT	D	Bristol-Myers Squibb	Multiple	NCT05209295	CA055-001	Y	Sutamtewagul	Grerk	ET	30-Apr-2024		I	N	Bas	N	A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Onureg®) in Subjects With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Adult Subjects With Myeloid Malignancies		12				
INT	D	Novartis Pharmaceuticals Corporation	Myeloid and Monocytic Leukemia	NCT05384587	CABL001AUS08	Y	Sy	Mario	ET	30-Jul-2024	21-Aug-2024	II	N	Tre	N	A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)		3	1	1		
INT	D	Pfizer Inc	Multiple Myeloma	NCT05090566	C1071004	Y	Tomasson	Michael	ET	07-Dec-2022	07-Mar-2024	II	N	Tre	N	A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA		15				

CTRP Data Table 4 Report (Interventional)	Cancer Center: Holden Comprehensive Cancer Center	Date Range: 01-Jan-2024 to 31-Dec-2024	Date Printed: 23-Mar-2025

CRC	STUDY SOURCE	SPECIFIC FUNDING SOURCE	PRIMARY SITE	NCT ID	PROTOCOL ID	IS MULTI INST?	PI - LAST NAME	PI - FIRST NAME	PROGRAM CODE	OPEN DATE	CLOSE DATE	PHASE	PILOT	PRIMARY PURPOSE	PRAG	OFFICIAL TITLE	ENTIRE STUDY	YOUR CENTER TOTAL	CENTER REPORTING PERIOD	CENTER TO DATE	OTHER REPORTING PERIOD	OTHER TO DATE
INT	D	Pfizer Inc	Breast	NCT06105632	C4391022	Y	Vikas	Praveen	ET	01-Aug-2024		II	N	Tre	N	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)		5				
INT	D	Gilead	Breast	NCT05382299	GS-US-592-6238	Y	Vikas	Praveen	ET	24-Oct-2023	03-Jun-2024	III	N	Tre	N	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1		10		1		
INT	D	Gilead	Breast	NCT05633654	GS-US-595-6184	Y	Vikas	Praveen	ET	19-Aug-2024		III	N	Tre	N	A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy		5	1	1		
INT	D	Merck Sharp & Dohme LLC	Kidney	NCT04626479	3475-03A	Y	Zakharia	Yousef	ET	16-May-2023	21-May-2024	I/II	N	Tre	N	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants		10				